Showing results (51-60 of 71) with videos related to
Sort By:
Pageof 8
Transplantation Proceedings|August 11, 2020
ABO-Incompatible Living Donor Kidney Transplantation in a Human Immunodeficiency Virus-Positive Recipient From a Human Immunodeficiency Virus-Positive Donor: A Case ReportShadi Katou, Thomas Vogel, Haluk Morgul, et al.Frontiers in Transplantation|July 12, 2024
Impact of everolimus plus calcineurin inhibitor on formation of non-HLA antibodies and graft outcomes in kidney transplant recipients: 12-month results from the ATHENA substudyAurélie Philippe, Wolfgang Arns, Vanessa Ditt, et al.Journal of Clinical Medicine|October 5, 2019
A Low Tacrolimus Concentration/Dose Ratio Increases the Risk for the Development of Acute Calcineurin Inhibitor-Induced NephrotoxicityGerold Thölking, Katharina Schütte-Nütgen, Julia Schmitz, et al.Kidney International|April 28, 2019
An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patientsClaudia Sommerer, Barbara Suwelack, Duska Dragun, et al.Frontiers in Transplantation|July 12, 2024
Everolimus plus reduced calcineurin inhibitor prevents de novo anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA studyWolfgang Arns, Aurélie Philippe, Vanessa Ditt, et al.Studies in Health Technology and Informatics|May 25, 2022
Metadata Definition in Registries: What Is a Data Element?Jürgen Stausberg, Sonja Harkener, Markus Burgmer, et al.Annals of Transplantation|March 23, 2016
Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver TransplantationGerold Thölking, Lea Siats, Christian Fortmann, et al.Clinical Transplantation|February 21, 2025
Myocardial Perfusion Scintigraphy Provides Incremental Prognostic Value in Patients on the Kidney Transplant Waiting ListStefan Reuter, Stefanie Reiermann, Jörg Stypmann, et al.European Journal of Immunology|December 11, 2020
Effect of everolimus-based drug regimens on CMV-specific T-cell functionality after renal transplantation: 12-month ATHENA subcohort-study resultsIngeborg A Hauser, Stefanie Marx, Claudia Sommerer, et al.HLA|December 24, 2021
Determination of unacceptable HLA antigen mismatches in kidney transplant recipientsMalte Ziemann, Barbara Suwelack, Bernhard Banas, et al.Pageof 8